Established hypertension is associated with abnormal exercise hemodynamics and reduced exercise capacity through mechanisms that may include contributions from arterial stiffness and endothelial vasomotor dysfunction. Phosphodiesterase type 5 (PDE5) inhibitors prolong nitric oxide-mediated cyclic guanosine monophosphate (cGMP) signaling in vascular smooth muscle, and have beneficial effects on exercise tolerance in pulmonary hypertension and heart failure. Recent studies suggest they may also be useful antihypertensive agents. We hypothesized they would reduce arterial stiffness and increase exercise capacity in hypertensive men.
Established hypertension is characterized by increased peripheral vascular resistance and a reduced exercise capacity, 1 which in turn is associated with increased cardiovascular morbidity and mortality. 2 Physical exercise increases blood flow to skeletal muscle, primarily through vasodilatation. In normotensive subjects, a delicate balance between vasodilatation and vasoconstriction leads to a progressive reduction of systemic vascular resistance during exercise, limiting the rise of systolic blood pressure (SBP). Exercise also results in favorable changes in arterial distensibility. 3, 4 By contrast, in hypertensive patients, exercise hemodynamics show an abnormal pattern characterized by lower stroke volume and, often, an exaggerated SBP response. 1 This abnormal pattern partly reflects an impaired peripheral vasodilator capacity, 5, 6 and may contribute to the reduced exercise capacity reported in hypertensive individuals. 7, 8 The mechanisms underlying the reduced exercise capacity and impaired peripheral vasodilatation found in hypertension are not fully understood but may include important contributions from endothelial vasomotor dysfunction and arterial stiffness, both of which are associated with hypertension. 9, 10 Moreover, both endothelial dysfunction and arterial stiffness are also associated with exercise hypertension. 11, 12 Endothelial dysfunction and arterial stiffness are also linked, because the endothelium, in part through the release of nitric oxide (NO), is an important regulator of arterial stiffness. 13 NO exerts its vasodilator effect on blood vessels through the formation of cyclic guanosine monophosphate (cGMP), which ultimately leads to relaxation of smooth muscle. 14 PDE5 inhibitors act by prolonging NO-mediated cGMP signaling in vascular smooth muscle, 15 and have been shown to improve exercise capacity in patients with pulmonary hypertension 16 and heart failure. 17, 18 We 19, 20 and others 21 have demonstrated that PDE5 inhibitors may be effective in lowering blood pressure (BP) in patients with essential hypertension, and we have also shown that sildenafil, but not the control vasodilator verapamil, improves the vasodilator response to handgrip exercise in hypertensive patients. 22 To date, no studies have investigated the effects of PDE5 inhibition on systemic exercise capacity in arterial hypertension. We hypothesized that sildenafil, as well as reducing BP, 19, 20 would improve exercise capacity and reduce arterial stiffness in hypertensive patients. To test our hypothesis, we investigated the effects of a 1-week treatment with oral sildenafil, hydralazine (a control cGMP-independent vasodilator and antihypertensive agent) and placebo on maximal exercise capacity, exercise SBP, and arterial stiffness in untreated hypertensive patients and matched normotensive subjects.
METHodS
The study was conducted with a 3-way crossover, randomized, placebo-controlled design. Sildenafil and matched placebo tablets were given double-blind, while hydralazine was unmatched and given single-blind (investigators blinded), as it was not possible to obtain hydralazine tablets of the same size and shape as the sildenafil tablets. The study was undertaken with the approval of the local Research Ethics Committee and in accordance with the Declaration of Helsinki. Written informed consent was obtained from each participant before entry into the study. The study was registered at ClinicalTrials.gov (NCT00599235).
Subjects
Sixteen hypertensive white men were recruited from the Cardiovascular Risk Clinic, Western General Hospital, Edinburgh ( Figure 1 ). Participants had sustained SBP >160 mm Hg and/or diastolic BP (DBP) >90 mm Hg measured 
Study protocol
Subjects attended at 9 am on 7 different occasions (1 preliminary visit and 2 study days for each treatment arm), each after an overnight fast (>12 hours). The study was composed of 3 periods, which were identical, except for the treatment, separated by at least a 1-week washout. During the initial preliminary visit all subjects had the opportunity to familiarize themselves with the exercise equipment and perform a practice run. They were then randomly assigned to oral sildenafil, hydralazine, or placebo and discharged with a supply of the assigned tablets to take 3 times daily for one week. They were also given a diary card in which to record the time of administration of each tablet and any symptoms experienced during the treatment.
Subjects were studied on day 7 and 8 of each treatment arm. On day 7, after 20 minutes resting in the sitting position, baseline measurements of BP and heart rate (HR) were made. Subjects then took their tablet and after 1 hour the same measurements were repeated. Subjects were then asked to stand up and, after 2 minutes, BP was recorded. This was followed by a 3-minute step test, at the end of which BP was immediately measured. On day 8, after 20 minutes resting in the supine position, the same preexercise procedure was repeated with the addition of carotid-femoral pulse wave velocity (CF-PWV) measurements, at baseline and 1 hour after drug administration. Subjects were then asked to perform an upright bicycle exercise to their maximum tolerance, with the use of a work rate progressively increasing at 20 watts per minute, after the first 2 minutes of unloaded pedaling. 22 Respiratory gas exchange variables were measured continuously during the unloaded cycling period and the exercise test and, in the absence of chest pain, ECG abnormalities, arrhythmias, or critical blood pressure changes (SBP >250 mm Hg and/or DBP >120 mm Hg), all tests were continued until exhaustion. The criteria used to establish maximal effort included a respiratory exchange ratio (RER) ≥1.10, a failure to maintain a pedaling rate above 40 rpm, and no change in HR with change in workload. At the end of the test, subjects rested supine for 1 hour and measurements of BP, HR, and CF-PWV were taken at 10, 40, and 60 minutes after exercise.
All measurements, except during exercise, were taken in duplicate and mean values entered into the analysis.
Measurements
Clinic BP and HR were monitored, with an appropriately sized cuff, using a validated oscillometric sphygmomanometer (HEM-705CP, Omron Corporation). 23 Assessment of exercise capacity and exercise BP. Exercise capacity was assessed through maximal incremental exercise testing on an electromagnetically braked cycle ergometer (Lode, Rehcor, Groningen, Netherlands) and measured as peak oxygen uptake (peak VO 2 ). Breath-by-breath gas analysis was performed using the Pulmolab EX670 mass spectrometer gas analyzer (Morgan Medical Ltd, Kent, UK), connected to a personal computer running analysis software. From this, peak VO 2 (defined as the highest 30-second average of oxygen uptake in the last minute of exercise) was derived. Predicted peak VO 2 for each subject was determined by using a protocol-specific formula. 24 The ventilatory anaerobic threshold was determined by the V-slope analysis method. 25 The relation of the increase in VO 2 to the increase in work rate (ΔVO 2 /ΔWR) and the peak oxygen pulse (the ratio of VO 2 and HR and a measure of the oxygen consumed per heart beat) were also calculated.
Exercise BP was measured immediately before exercise and every 2 minutes during exercise using an exercise-validated ECG-gated auscultatory device (Tango+ exercise BP monitor, SunTech Medical Instruments, NC). 26 Continuous 12-lead ECG monitoring was performed during each test for assessment of HR, arrhythmias, and myocardial ischemia.
Exercise BP was also assessed in response to the Dundee step test. This is a single-stage test of light exercise consisting of each subject stepping up and down (step height 17.5 cm) for 3 minutes, at a fixed rate of 92 steps per minute. 27 Exercise BP was measured with the Tango+ before exercise and immediately after 3 minutes of stepping.
Assessment of arterial stiffness. The SphygmoCor apparatus (AtCor Medical Pty Ltd, West Ride, Australia) was used to measure CF-PWV, a reliable measure of arterial stiffness. 19 We can report that postexercise aortic PWV reproducibility data have a repeatability coefficient of 0.9.
drugs
Sildenafil citrate 50 mg and matched placebo tablets were obtained from Pfizer Ltd (Sandwich, Kent, UK), and administered 3 times daily. Hydralazine 25 mg (Alpharma, Barnstaple, Devon, UK) was administered 3 times daily as a cGMP-independent vasodilator control. Hydralazine has been previously used in studies involving healthy subjects and hypertensive patients 28, 29 and, after oral administration, peak plasma concentrations are reached within 30 to 90 minutes (median 60 minutes), 30 showing a time to peak effect similar to sildenafil. 31 We selected doses of hydralazine and sildenafil that we expected would produce similar BP reductions. 19, 32 Treatment was allocated by a research nurse independent of the study. Subjects were given 25 tablets for each treatment arm and asked to return all tablets left at the end of the treatment to determine adherence.
Statistical analyses
Sample size calculations, made on the basis of published data, indicated that 30 subjects (15 for each group) would have 80% power to detect a 25% difference in peak VO 2 between treatment arms at the 5% level. 33, 34 Results are presented as mean ± SEM. Repeated measures analysis of variance (ANOVA), with post hoc Bonferroni corrections, was used to assess the effect of time and intervention within each group. Differences between groups were analyzed by 2-tailed unpaired Student t test as appropriate. Statistical analysis was performed with GraphPad Prism software (San Diego, CA).
rESuLTS
The clinical characteristics of the study subjects are shown in Table 1 . A total of 30 subjects (15 for each group) completed the study. During cardiopulmonary exercise testing none of the subjects had to stop because of chest pain, ECG abnormalities, arrhythmias, or critical BP changes. The only reason for stopping exercise was leg fatigue in both groups. Mean adherence (calculated based upon returned tablets) was 97% during the placebo arm, 96% during the sildenafil arm, and 97% during the hydralazine arm.
Following placebo, BP and CF-PWV were significantly higher in hypertensive patients than normotensive subjects at all time points (ANOVA P < 0.0001; Tables 2 and 3 ). In addition, with placebo treatment, after exercise, CF-PWV significantly increased compared with baseline values in hypertensive patients at +40 and +60 minutes, whereas this increase was not observed in the normotensive group (Table 3) . Changes in SBP with respect to baseline during the step test (day 7, data not shown) and at peak exercise (day 8, Table 4) , were not significantly different between groups. Hypertensive patients also exhibited lower peak VO 2 (P < 0.01), VO 2 at anaerobic threshold (ANOVA P < 0.05), peak workload (P < 0.05), exercise time (P < 0.05), and lower VO 2 /work rate relationship (P < 0.01) than normotensive subjects (Table 4) .
Effects of drug treatments
The effects of sildenafil and hydralazine on BP and CF-PWV are shown in Tables 2 and 3 . In the normotensive group baseline SBP and DBP was not different from placebo after 1 week of drug treatment. In hypertensive patients, baseline SBP was lower after drug treatment than after placebo, although this decrease reached statistical significance only for hydralazine (P < 0.05); with respect to DBP, the decrease was significant for both sildenafil (P < 0.01) and hydralazine (P < 0.05). In both groups, BP did not change significantly 1 hour after drug administration compared with baseline. On exercise days (day 7 and 8 of the treatment), postexercise BPs with respect to baseline were not significantly different between groups, and were not affected by drug treatment. Peak VO 2 and related parameters are shown in Table 4 . A mean peak RER ≥1.10 was achieved in both groups during each study day, consistent with maximum effort during exercise. Sildenafil and hydralazine did not affect peak VO 2 or VO 2 at anaerobic threshold in either group.
During the recovery period after exercise, hydralazine reduced SBP compared with baseline in the hypertensive group (ANOVA P = 0.0002), whereas sildenafil did not. In the normotensive group, CF-PWV was not affected by either sildenafil or hydralazine treatment at any time point after exercise. By contrast, in hypertensive patients, CF-PWV was significantly lower after exercise following sildenafil treatment but not after placebo or hydralazine (ANOVA P = 0.0001; Table 3 and Figure 2 ).
adverse effects
Two subjects, one from each group, discontinued the study medication because of severe headache, one while taking sildenafil and the other placebo, and both were withdrawn from the study. Both subjects were on the first treatment arm and were not considered in the final analyses, which therefore included fully paired data. In the subjects who completed the study, headache was the most common symptom reported in the normotensive group while on sildenafil (n = 4), followed by dyspepsia (n = 3), and low back pain (n = 2). Headache was also the most common symptom reported by Table 2 . Systolic blood pressure, diastolic blood pressure, and heart rate 1 hour after drug administration and after cardiopulmonary exercise testing Heart rate (bpm) Baseline 61 (2) 60 (3) 65 (3) 64 (2) 68 (2) 69 ( For absolute values comparisons are against baseline; for Δ (changes) from baseline comparisons are among placebo, sildenafil, and hydralazine.
Abbreviations: bpm, beats per minute; DBP, diastolic blood pressure; P, placebo; SBP, systolic blood pressure.
*P < 0.05, †P < 0.01, ‡P < 0.001. normotensive subjects while on hydralazine (n = 4). In the hypertensive group, the most common symptom reported while on sildenafil was dyspepsia (n = 8), followed by headache (n = 6) and low back pain (n = 4). While on hydralazine, nasal congestion was reported by 3 subjects, followed by headache (n = 2) and dry throat (n = 2). Increased penile erection was reported by a total of 6 subjects (3 from each group) while taking sildenafil.
diScuSSion
In this study we have confirmed that hypertensive patients have reduced exercise capacity compared with normotensive subjects. Treatment with the PDE5 inhibitor sildenafil did not affect peak VO 2 , an index of maximal exercise capacity, or the BP response to exercise. However, it did reduce the postexercise increase in CF-PWV, the "gold standard" measure of arterial stiffness, in hypertensive white men, an effect not observed with placebo or hydralazine treatment.
After placebo, BP and CF-PWV were significantly higher in hypertensive patients than normotensive subjects at all time points. Furthermore, in the recovery period after exercise, CF-PWV significantly increased compared with baseline values in hypertensive patients consistent with an impaired vascular response to exercise, whereas this increase was not observed in the normotensive group. There are limited data on the effect of exercise on arterial stiffness in normal subjects. Naka et al reported a reduction in upper and lower limb PWV but did not measure aortic PWV. 4 Munir reported no change in PWV with exercise, but used a submaximal exercise protocol. 3 Peak VO 2 and VO 2 at anaerobic threshold were significantly lower in our hypertensive individuals, as well as the changes in the VO 2 /work rate relationship, which reflects a smaller increase in VO 2 with work rate compared with normotensive individuals.
In hypertensive patients, baseline BP was lower after drug treatment compared with the placebo arm, confirming a BP-lowering effect of both drugs after 1 week of treatment. However, 1 hour after drug administration, BP was not significantly different from baseline, in agreement with another report from our group. 19 On both exercise days the magnitude of the exercise-induced increase in SBP was not significantly different between hypertensive and normotensive subjects, consistent with other published work, 35 and the type of treatment made no difference overall.
In our study, PDE5 inhibition did not affect peak VO 2 or any of the other parameters measured at peak exercise in hypertensive patients. This suggests that, unlike conditions such as pulmonary hypertension and heart failure, an impaired NO-cGMP pathway does not significantly contribute to the reduced systemic exercise capacity in arterial hypertension. In studies involving patients with pulmonary hypertension and heart failure, the favorable effects observed with PDE5 inhibition seem to be consistently related to a reduction of pulmonary vascular resistance. Indeed, the improved exercise capacity reported with sildenafil in patients with heart failure is mainly observed in those with secondary pulmonary hypertension. 36 In support of this, and in agreement with our findings in the control group, current evidence shows that, in healthy subjects, sildenafil only improves exercise Table 3 . Carotid-femoral pulse wave velocity at baseline, 1 hour after drug administration and after cardiopulmonary exercise testing For absolute values comparisons are against baseline; for Δ (changes) from baseline comparisons are among placebo sildenafil and hydralazine.
Abbreviations: H, hydralazine; P, placebo. *P < 0.05, †P < 0.01, ‡P < 0.001. capacity in hypoxic conditions, which elicit a pulmonary hypertensive response. 37 When we compared the effects of the 3 interventions on CF-PWV after exercise, no significant difference was observed in our healthy controls. By contrast, in the hypertensive patients, we detected a significant difference among the 3 treatments in favor of sildenafil, which reduced CF-PWV after exercise, an effect that was not observed with the control vasodilator hydralazine. Between 10 and 60 minutes after exercise, sildenafil did not cause any significant change in BP, therefore changes in distending pressure cannot explain the observed increase in arterial distensibility, suggesting that this may be due to a direct effect of the drug on the arterial wall. However, the effect of sildenafil on CF-PWV was significantly different from hydralazine only at a single time point after exercise, and this observation needs to be confirmed and its clinical significance determined. Nonetheless, sildenafil did reduce CF-PWV after exercise at all time points, reaching statistical significance at 40 minutes and 60 minutes postexercise, though not at 10 minutes postexercise.
Hypertensive patients recruited for the study represented a carefully selected group in whom hypertension was the only identified cardiovascular risk factor. We did not directly address endothelial dysfunction in this already demanding study, but the BP cutoff point (160/90 mm Hg) was chosen in order to enhance the contrast between the hypertensive and normotensive subjects, presumably increasing the likelihood of including patients with significant endothelial dysfunction.
The short duration of the treatment may not have been sufficient for PDE5 inhibition to influence exercise capacity in our hypertensive subjects. However, other studies have shown that sildenafil improves markers of endothelial function after only 1 week of treatment in men with type 2 diabetes. 38 Indeed, in patients with pulmonary hypertension and heart failure, sildenafil has been shown to improve exercise capacity after only a single dose. 39, 40 The number of parameters analyzed at different time points required multiple statistical comparisons, and we cannot discount the possibility of a type I statistical error. However, to minimize the occurrence of this error, Bonferroni correction was applied to all comparisons, and the effect of sildenafil on PWV was still highly significant (P < 0.01).
PDE5 inhibition with sildenafil did not improve exercise capacity in hypertensive white men. Nevertheless, our results suggest that PDE5 inhibition might be useful in reducing arterial stiffness in the recovery period after exercise, although these findings need to be confirmed in further studies.
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